Table 1. Clinical and Molecular Characteristics of IDH-Mutated PMF Patients.

UPN	Age	G	Karyotype	IDH	JAK2 (allele burden)	FU	OS	Drug	Survival
1*	82	F	Normal	IDH1 R132C	(-)	5	5	Hydroxyurea	Death
2	59	F	Normal	IDH1 R132C	(-)	24	24	Hydroxyurea	Death
3	86	F	Normal	IDH1 R132C	(+) (31-50%)	187	187	Hydroxyurea	Death
4	57	F	Normal	IDH1 R132S	(+) (5-12.5%)	284	284	Hydroxyurea	Alive
5	37	F	Normal	IDH2 R140Q	(+) (31-50%)	4	4	Hydroxyurea	Alive

UPN indicates unique patient number. G: gender; F: female; FU: follow-up (months); OS: overall survival (months). *Patient with leukemic transformation.